Reversal of Ventricular Remodeling With Toprol-XL
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00038077 |
Recruitment Status :
Completed
First Posted : May 29, 2002
Last Update Posted : November 19, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Heart Failure, Congestive | Drug: Seloken ZOK/Toprol-XL Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 300 participants |
Allocation: | Randomized |
Masking: | Double |
Primary Purpose: | Treatment |
Study Start Date : | August 2001 |
Actual Primary Completion Date : | September 2003 |
Actual Study Completion Date : | September 2003 |

- Drug: Seloken ZOK/Toprol-XL
50 mgOther Name: Toprol-XL
- Drug: Seloken ZOK/Toprol-XL
200 mgOther Name: Toprol-XL
- Drug: Placebo

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of stable asymptomatic heart failure.
- Documented ejection fraction less than 0.40.
- Must be able to comply with all study procedures.
Exclusion Criteria:
- Taken B-blocker therapy for longer than 1 week within 6 months prior to randomization.
- Have heart problems that would not allow B-blocker therapy.
- Receiving B-blockers therapy for any medical reason including topical B-blockers that might cause systemic absorption (e.g., glaucoma).
- Undergone certain heart surgeries, such as, prior heart transplant or cardiomyoplasty.
- Have certain heart diseases.
- Pregnant or breast feeding.
- Unlikely to survive.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00038077
United States, Alabama | |
Birmingham, Alabama, United States | |
Mobile, Alabama, United States | |
United States, Arkansas | |
Little Rock, Arkansas, United States | |
United States, California | |
Los Angeles, California, United States | |
Northridge, California, United States | |
Redondo Beach, California, United States | |
Riverside, California, United States | |
United States, Connecticut | |
Research Site | |
Farmington, Connecticut, United States | |
United States, Florida | |
Clearwater, Florida, United States | |
Melbourne, Florida, United States | |
Vero Beach, Florida, United States | |
United States, Georgia | |
Augusta, Georgia, United States | |
United States, Indiana | |
Indianapolis, Indiana, United States | |
Jeffersonville, Indiana, United States | |
United States, Kentucky | |
Edgewood, Kentucky, United States | |
United States, Louisiana | |
New Orleans, Louisiana, United States | |
Shreveport, Louisiana, United States | |
United States, Maine | |
Auburn, Maine, United States | |
United States, Maryland | |
Baltimore, Maryland, United States | |
Salisbury, Maryland, United States | |
United States, Massachusetts | |
Boston, Massachusetts, United States | |
United States, Missouri | |
St. Charles, Missouri, United States | |
St. Louis, Missouri, United States | |
United States, Nebraska | |
Omaha, Nebraska, United States | |
United States, New Mexico | |
Albuquerque, New Mexico, United States | |
United States, New York | |
Bronx, New York, United States | |
Buffalo, New York, United States | |
E. Syracuse, New York, United States | |
New York, New York, United States | |
Rochester, New York, United States | |
Williamsville, New York, United States | |
United States, North Carolina | |
Burlington, North Carolina, United States | |
United States, Ohio | |
Columbus, Ohio, United States | |
United States, Oklahoma | |
Oklahoma City, Oklahoma, United States | |
United States, Pennsylvania | |
Flourtown, Pennsylvania, United States | |
Philadelphia, Pennsylvania, United States | |
Pittsburgh, Pennsylvania, United States | |
United States, Rhode Island | |
Lincoln, Rhode Island, United States | |
Wakefield, Rhode Island, United States | |
United States, Texas | |
Tyler, Texas, United States | |
United States, Utah | |
Salt Lake City, Utah, United States | |
United States, Virginia | |
Chesapeake, Virginia, United States | |
Roanoke, Virginia, United States | |
United States, Wisconsin | |
Green Bay, Wisconsin, United States |
ClinicalTrials.gov Identifier: | NCT00038077 |
Other Study ID Numbers: |
276 USMET0002 |
First Posted: | May 29, 2002 Key Record Dates |
Last Update Posted: | November 19, 2010 |
Last Verified: | November 2010 |
Heart Failure Heart Diseases Cardiovascular Diseases Metoprolol Anti-Arrhythmia Agents Antihypertensive Agents Sympatholytics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Adrenergic beta-1 Receptor Antagonists Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |